Thureau Sébastien, Lebret Lucie, Lequesne Justine, Cabourg Marine, Dandoy Simon, Gouley Céline, Lefebvre Laureline, Mallet Romain, Mihailescu Sorina-Dana, Moldovan Cristian, Rigal Olivier, Veresezan Ovidiu, Modzewelski Romain, Clatot Florian
Department of Radiation Oncology, Henri Becquerel Cancer Center & QuantIF-LITIS [EA (Equipe d'Accueil) 4108], 76038 Rouen, France.
Department of Radiation Oncology, Henri Becquerel Cancer Center, 76038 Rouen, France.
Cancers (Basel). 2021 Feb 11;13(4):753. doi: 10.3390/cancers13040753.
Sarcopenia is frequent in patients treated with radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinomas. Sarcopenia is associated with poor disease-free survival and overall survival outcomes. Sarcopenia is not associated with a higher rate of treatment-related toxicity. Sarcopenia occurs frequently with the diagnosis of head and neck squamous cell carcinoma (HNSCC). We aimed to assess the impact of sarcopenia on survival among HNSCC patients treated with radiotherapy (RT) or radiochemotherapy (RTCT). Patients treated between 2014 and 2018 by RT or RTCT with curative intent were prospectively included (NCT02900963). Optimal nutritional support follow-up, including weekly consultation with a dietician and an oncologist and daily weight monitoring, was performed. Sarcopenia was determined by measuring the skeletal muscles at the L3 vertebra on the planning CT scan for radiotherapy. For each treatment group (RT or RTCT), we assessed the prognostic value of sarcopenia for disease-free survival (DFS) and overall survival (OS) and its impact on treatment-related toxicity. Two hundred forty-three HNSCC patients were included: 116 were treated by RT and 127 were treated by RTCT. Before radiotherapy, eight (3.3%) patients were considered malnourished according to albumin, whereas 88 (36.7%) patients were sarcopenic. Overall, sarcopenia was associated with OS and DFS in a multivariate analysis (HR 1.9 [1.1-3.25] and 1.7 [1.06-2.71], respectively). It was similar for patients treated with RT (HR 2.49 [1.26-4.9] for DFS and 2.24 [1.03-4.86] for OS), whereas for patients treated with RTCT sarcopenia was significantly associated with OS and DFS in univariate analysis only. Sarcopenia was not related to higher treatment-related toxicity. Pretherapeutic sarcopenia remains frequent and predicts OS and DFS for non-frail patients treated with curative intent and adequate nutritional support.
肌肉减少症在接受头颈部鳞状细胞癌放射治疗(RT)或放化疗(RTCT)的患者中很常见。肌肉减少症与无病生存期和总生存期较差相关。肌肉减少症与较高的治疗相关毒性发生率无关。肌肉减少症常与头颈部鳞状细胞癌(HNSCC)的诊断同时出现。我们旨在评估肌肉减少症对接受放疗(RT)或放化疗(RTCT)的HNSCC患者生存的影响。前瞻性纳入了2014年至2018年间接受根治性RT或RTCT治疗的患者(NCT02900963)。进行了最佳营养支持随访,包括每周与营养师和肿瘤学家会诊以及每日体重监测。通过在放疗计划CT扫描上测量L3椎体的骨骼肌来确定肌肉减少症。对于每个治疗组(RT或RTCT),我们评估了肌肉减少症对无病生存期(DFS)和总生存期(OS)的预后价值及其对治疗相关毒性的影响。纳入了243例HNSCC患者:116例接受RT治疗,127例接受RTCT治疗。放疗前,根据白蛋白水平,8例(3.3%)患者被认为营养不良,而88例(36.7%)患者存在肌肉减少症。总体而言,在多变量分析中,肌肉减少症与OS和DFS相关(HR分别为1.9[1.1 - 3.25]和1.7[1.06 - 2.71])。接受RT治疗的患者情况类似(DFS的HR为2.49[1.26 - 4.9],OS的HR为2.24[1.03 - 4.86]),而对于接受RTCT治疗的患者,仅在单变量分析中肌肉减少症与OS和DFS显著相关。肌肉减少症与较高的治疗相关毒性无关。治疗前肌肉减少症仍然很常见,并且可以预测接受根治性治疗且营养支持充足的非体弱患者的OS和DFS。